Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8366653 | 0.83 | CYP1A2 (0.54) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10492869 | 0.80 | HRH4 (0.52) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14311148 | 0.80 | LMNA (0.57) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7745152 | 0.80 | RAB9A (1.00) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15693610 | 0.79 | RAB9A (0.64) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15693620 | 0.78 | CYP1A2 (0.62) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10492786 | 0.78 | MEN1 (0.64) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10492777 | 0.78 | CYP1A2 (0.43) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10844608 | 0.78 | AR (0.44) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4597359 | 0.77 | ALDH1A1 (0.53) | RAB9ASMN1; SMN2CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | DIAKRON PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | AGTR2, ACE, AGTR1 | RAB9A 2789/4885SMN1; SMN2 3210/4885CYP1A2 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.